Stock A069620 DAEWOONG PHARMACEUTICAL CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Daewoong Pharmaceutical Co., Ltd

Equities

A069620

KR7069620003

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-06-27 EDT 		5-day change 1st Jan Change
102,400 KRW +0.89% Intraday chart for Daewoong Pharmaceutical Co., Ltd -0.10% -12.33%
05-14 Daewoong Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-24 Korean Sugar Imports Plunge 14% as Diabetes Cases Surge MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,419,120 1,775,845 1,638,243 1,754,469 1,343,932 1,178,242 - -
Enterprise Value (EV) 2 1,783 2,155 2,037 1,754 1,762 1,664 1,550 1,895
P/E ratio 70.2 x 561 x 45.5 x 36.1 x 12 x 14.4 x 9.84 x 10.8 x
Yield 0.44% 0.36% 0.41% - 0.51% 0.59% 0.59% 0.59%
Capitalization / Revenue 1.41 x 1.88 x 1.55 x 1.51 x 1.1 x 0.93 x 0.87 x 0.82 x
EV / Revenue 1.77 x 2.28 x 1.93 x 1.51 x 1.44 x 1.31 x 1.14 x 1.31 x
EV / EBITDA 28.6 x 47.2 x 15.9 x 12.7 x 10.4 x 9.07 x 7.56 x 7.42 x
EV / FCF 94.4 x 27.9 x 73.4 x - 32.7 x 17 x 12 x 15.5 x
FCF Yield 1.06% 3.59% 1.36% - 3.05% 5.89% 8.3% 6.44%
Price to Book 2.57 x 3.08 x 2.79 x - 1.66 x 1.37 x 1.3 x 1.12 x
Nbr of stocks (in thousands) 10,321 10,763 11,069 11,069 11,506 11,506 - -
Reference price 3 137,500 165,000 148,000 158,500 116,800 102,400 102,400 102,400
Announcement Date 2/13/20 2/15/21 2/15/22 2/15/23 2/5/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,005 944.8 1,055 1,161 1,222 1,270 1,356 1,442
EBITDA 1 62.4 45.62 128.4 138 169.1 183.4 205.1 255.5
EBIT 1 31.45 12.63 95.5 106 133.4 144.9 165.7 204.5
Operating Margin 3.13% 1.34% 9.05% 9.12% 10.92% 11.41% 12.22% 14.18%
Earnings before Tax (EBT) 1 16.41 -7.785 31.72 85.74 111.6 86 140.2 139.5
Net income 1 20.23 3.139 40.48 80.14 111.5 68 117.6 109.5
Net margin 2.01% 0.33% 3.84% 6.9% 9.12% 5.35% 8.67% 7.59%
EPS 2 1,960 294.0 3,253 4,387 9,760 7,136 10,410 9,472
Free Cash Flow 3 18,884 77,281 27,763 - 53,809 98,000 128,667 122,000
FCF margin 1,878.63% 8,180.05% 2,631.18% - 4,403.35% 7,714.11% 9,492.05% 8,460.47%
FCF Conversion (EBITDA) 30,260.08% 169,393.08% 21,618.49% - 31,826.84% 53,420.55% 62,733.63% 47,749.51%
FCF Conversion (Net income) 93,353.69% 2,462,165.05% 68,580.57% - 48,259.15% 144,117.65% 109,456.97% 111,415.53%
Dividend per Share 2 600.0 600.0 600.0 - 600.0 600.0 600.0 600.0
Announcement Date 2/13/20 2/15/21 2/15/22 2/15/23 2/5/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 275.3 272.2 293.8 301.5 293.8 292.3 307.1 303 319.6 296.6 323 329.4 332.8
EBITDA 1 - - 41.44 38.25 23.45 39.25 45.02 43.17 41.63 40.99 46.25 46.65 46.8
EBIT 1 24.71 26.77 33.57 30.31 15.3 30.97 36.19 34.2 32.04 31.23 42.6 36.6 37.1
Operating Margin 8.97% 9.84% 11.43% 10.05% 5.21% 10.6% 11.79% 11.29% 10.03% 10.53% 13.19% 11.11% 11.15%
Earnings before Tax (EBT) 20.26 24.17 27.71 28.96 4.897 27.16 31.99 26.11 26.42 13.94 - - -
Net income 34.85 17.52 20.74 21.51 20.38 20.47 28.76 19.76 42.5 10.83 - - -
Net margin 12.66% 6.44% 7.06% 7.13% 6.93% 7% 9.37% 6.52% 13.3% 3.65% - - -
EPS - - - - - 1,832 - - - - - - -
Dividend per Share - - - - - - - - - - - - -
Announcement Date 2/15/22 4/28/22 7/28/22 10/31/22 2/15/23 5/3/23 7/27/23 10/27/23 2/5/24 4/29/24 - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 364 379 399 - 418 486 372 717
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 5.829 x 8.317 x 3.106 x - 2.472 x 2.649 x 1.815 x 2.806 x
Free Cash Flow 2 18,884 77,281 27,763 - 53,809 98,000 128,667 122,000
ROE (net income / shareholders' equity) 3.71% 0.56% 6.01% - 15.2% 12.4% 14.2% 10.9%
ROA (Net income/ Total Assets) 1.86% 0.27% 2.93% - 7.59% 4.25% 7.08% 5.7%
Assets 1 1,088 1,143 1,383 - 1,470 1,600 1,660 1,921
Book Value Per Share 3 53,580 53,521 53,015 - 70,283 74,622 78,902 91,325
Cash Flow per Share 3 3,681 9,225 4,357 - 11,604 12,002 14,193 14,083
Capex 1 19.1 21.1 20.2 - 78.8 65 54.3 77
Capex / Sales 1.9% 2.23% 1.91% - 6.45% 5.12% 4.01% 5.34%
Announcement Date 2/13/20 2/15/21 2/15/22 2/15/23 2/5/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Daewoong Pharmaceutical Co., Ltd

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
DAEWOONG PHARMACEUTICAL CO., LTD Stock Daewoong Pharmaceutical Co., Ltd
-12.33% 842M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.76% 43.59B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+28.00% 22.54B
SANDOZ GROUP AG Stock Sandoz Group AG
+20.25% 15.73B
CIPLA LIMITED Stock Cipla Limited
+18.82% 14.33B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+55.83% 12.75B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-12.70% 6.48B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+14.65% 5.67B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A069620 Stock
  4. Financials Daewoong Pharmaceutical Co., Ltd